Analysis of causes of failure of medical treatment in patients undergoing surgery for benign prostate enlargement

Abstract

Background:

To analyse causes of failure of medical management in benign prostate enlargement (BPE) in patients who undergo surgery following medical treatment and to elucidate parameters which warrant for early surgical treatment.

Methods:

Records of 747 patients who underwent surgery for BPE were reviewed for prostate volume, median lobe enlargement, post void residual urine, duration and type of medical treatment given for BPE. We used univariate and multivariate analysis to find out significant parameters for medical treatment failure.

Results:

A total of 601 patients (80.45%) received medical treatment for their lower urinary tract symptoms (LUTS), for a duration ranging between 3 months and 2 years. Statistically significant difference was found between age, prostate volume, intravesical projection, PSA and acute urinary retention with failure of medical treatment.

Conclusions:

BPE patients with failure to respond with medical management within 3–6 months and/or associated with large size prostate, intravesical projection and raised serum PSA should better be offered surgical treatment.

Keywords

BPE failure of medical treatment for BPE LUTS medical treatment of BPE surgical treatment of BPE

Get full access to this article

View all access options for this article.

References

Pickard

Emberton

Neal

DE.

The management of memn with acute urinary retention. National prostatectomy audit steering group. Br J Urol 1998; 81: 712–720.

Emberton

Andriole

de la Rosette

, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003; 61: 267–273.

de la Rosette

Alivizatos

Madersbacher

, et al. European Urological Association guidelines on BPH, 2002. Available at http://www.uroweb.nl/files/uploadedfiles/guidelines/updateBPH.pdf (accessed September 2004).

Djavan

Marberger

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1–13.

Roehrborn

Bruskewitz

Nickel

, et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 2004; 171(3): 1194–1198.

Kaplan

McConnell

Roehrborn

, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 2006; 175(1): 217–220.

McConnell

JD.

The long term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J Urol 2002; 167(suppl): 1042A.

Boyle

Gould

Roehrborn

CG.

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398–405.

Lukacs

Grange

Comet

One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. Urology 2000; 55: 540–546.

10.

Teillac

Scarpa

RM.

Economic issues in the treatment of BPH. Eur Urol 2006; 5: 1018–1024.

11.

McVary

KT.

A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 2007; 29(3): 387–398.

12.

Roehrborn

CG.

Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol 2008; 10(1): 14–25.

13.

Roberts

Jacobsen

Jacobson

, et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 2000; 163: 107–113.

14.

Jacobsen

Jacobson

Girman

, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481–487.

15.

Foo

KT.

What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?

World J Urol 2019; 37: 1293–1296.

16.

Marberger

Andersen

Nickel

, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 2000; 38: 563–568.

17.

Roehrborn

McConnell

Lieber

, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999; 53: 473–480.

18.

Roehrborn

Barkin

Siami

, et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind combination of Avodart and tamsulosin (CombAT) trial. BJU Int 2011; 107(6): 946–954.